Analytical methods
Genomic sequencing of the coding regions of the commonest causative genes has been most frequently employed to search for BBS mutations. Gene-sequencing panels have more recently become available (see Section 2.3). Large deletions and genomic rearrangements are rare and array comparative genomic hybridization and karyotyping are not routinely performed. 2 
Analytical validation
Sequence alterations that could be mutations are bidirectionally sequenced and can be re-sequenced in normal, ethnically matched controls to exclude polymorphisms.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) The incidence of BBS has been estimated to be 1 in 100 000 to 1 in 160 000 live births in both the North American and European populations. 5 
Abbreviations: Del, intragenic deletion; F, frameshift mutation; M, missense mutation; N, nonsense mutation; S, splice site mutation. a Estimated mutation frequency. [2] [3] [4] After 
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
The sensitivity for genomic sequencing approaches 100% for mutation detection, but errors can be made due to polymorphisms causing allele dropout. Deletions of whole exons or whole gene deletions are not usually detected by sequencing, and mutations outside the coding exons in promoters or enhancers are likely to be missed. However, these mutational mechanisms are probably uncommon in BBS.
Analytical specificity (proportion of negative tests if the genotype is not present)
Analytical specificity is nearly 100%. False positives in genomic sequencing are rare.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Mutation frequency for the 14 known BBS genes has been provided in Section 1.5.
Panels that screen multiple causative genes in BBS can achieve a higher sensitivity than single-gene analysis. Using clinical panels for screening multiple BBS genes leads to an estimated sensitivity of 70%. 10 It is important to note that many of the clinical manifestations of BBS are age dependent, and that the average age of diagnosis in a study of 109 individuals was 9 years. 6 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Clinical specificity is nearly 100%.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
BBS has two modes of inheritance -autosomal recessive and triallelic/oligogenic inheritance. For BBS inherited as an autosomal recessive trait, non-penetrance is rare and positive clinical predictive value approaches 100%, although milder BBS phenotypes have been described. 11 Triallelic/oligogenic inheritance requires two disease-causing mutations at one BBS locus, with a third mutation at a different locus. In families with triallelic/oligogenic inheritance, two disease-causing mutations may be insufficient to cause clinical features, although this type of inheritance is infrequent in BBS.
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: Nearly 100%.
Index case in that family had not been tested: Genetic heterogeneity with undiscovered genes means that 20-30% of individuals who test negative for all of the currently known BBS genes may still have the condition. for a clinical diagnosis of BBS. 6 It is crucial that clinicians are aware of the age dependency of some of the more important diagnostic findings, with onset of obesity after infancy, developmental differences in early childhood and the onset of visual impairment in later childhood or teenage years.
CLINICAL UTILITY
Describe the burden of alternative diagnostic methods to the patient
A clinical diagnosis may require at a minimum a history and physical examination, measurement of growth parameters, an optical fundus examination and/or an electroretinogram, a renal ultrasound scan, and a developmental assessment.
How is the cost effectiveness of alternative diagnostic methods to be judged?
Although an accurate clinical assessment can substantiate the diagnosis of BBS and therefore establish the need for appropriate monitoring and management, genetic testing remains useful for genetic counseling and prenatal testing.
Will disease management be influenced by the result of a genetic test?
3.2 Predictive Setting: The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe): See above (Section 3.1).
If the test result is negative (please describe): Follow-up required. Multidisciplinary clinic management is optimal, but often single-specialist referrals are obtained, including ophthalmology, nephrology, nutrition and endocrinology.
